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Abstract
Background: A close association between Sst I polymorphism in the 3' untranslated region of the
apolipoproteinC3 (APOC3) gene and levels of plasma triglycerides (TG) had been reported by
different investigators. Hypertriglyceridemia(HTG) is a known risk factor for coronary artery
disease (CAD) in the context of Asian Indians. We conducted a study on the relationship between
APOC3 SstI polymorphism (S1S1, S1S2 and S2S2 genotypes) and plasma TG levels in a group of 139
male healthy volunteers from Northern India.
Methods: DNA samples were analyzed by polymerase chain reaction (PCR) followed by SstI
digestion. Digested PCR products were run on 3% agarose gel and visualized by ethidium bromide
staining.
Results: Rare S2 allele was highly prevalent in our study population (0.313) as compared to the
Caucasians (0.00–0.11). The genotypic distribution was in agreement with Hardy-Weinberg
equilibrium. S2 allele was almost two times more prevalent in the HTG group (N = 34) as compared
to NTG group (N = 105) (p = 0.001). Multiple logistic regression revealed S1S2 individuals had age-
adjusted odds ratio of 2.43 (95%CI = 0.99–6.01, p = 0.054) and S2S2 had 9.9 (95%CI = 2.66–37.29,
p = 0.0006) for developing HTG in comparison to S1S1 genotype.
Conclusions: Our study shows a significant association between rare S2 allele and HTG in Asian
Indians.
Background
Apolipoprotein CIII (apoCIII protein; APOC3 gene) is a
79 amino acids long glycoprotein that is synthesized pre-
dominantly in the liver and to a lesser degree in the intes-
tine [1]. It is present on very low density lipoproteins
(VLDLs) and chylomicron remnants; and to some extent
on high density lipoproteins (HDLs) [1]. Although the
precise function of apoCIII is not clearly understood, sev-
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eral lines of evidence suggest its involvement in the regu-
lation of triglyceride (TG) levels. In vitro, apoCIII inhibits
lipoprotein lipase (LPL), a rate-limiting enzyme for TG
hydrolysis, resulting in the delayed catabolism of TG-rich
particles [2]. Furthermore, it also decreases apoE-mediat-
ed remnant removal by displacement of apoE from the
VLDL particles in vivo [3,4]. Additional copies of human
APOC3 gene in transgenic mice were associated with
hypertriglyceridemia (HTG) [5], whereas the absence of
the gene in knock out mice leads to reduced TG [6].
APOC3 gene has been mapped on the long arm of
chromosome11, closely linked to the APOA4 and APOA1
genes [7]. A transversion from C to G in the 3' untranslat-
ed region (3'UTR) of exon 4 in the APOC3 gene results in
an SstI polymorphism. Several studies have suggested a
close association between rare S2 allele of SstI polymor-
phism and elevated TG levels [8–24] and apoCIII levels
[22–25]. However, few other studies have shown contra-
dictory results [26–31].
We have investigated the association of APOC3 SstI poly-
morphism with TG levels in a group of healthy volunteers
from Northern India; considering the high prevalence of
CAD in Asian Indians, HTG as one of the underlining risk
factors in the progression of coronary atherosclerosis [32]
and no information available on Asian Indians in this
context.
Results
The characteristics of the NTG and HTG groups are shown
in Table 1. There was no significant difference in the mean
age between the two groups (p = 0.748). TC (p = 0.0001)
and TG levels (p < 0.0001) were significantly higher in the
HTG group as compared to the NTG group. There was no
significant difference in LDL, HDL and LDL/HDL ratio.
The genotypic and allelic distribution of APOC3 polymor-
phism in the study population is shown in Table 2. No
observed in the study population. The frequency of the S2
allele in the study population was 0.313 (Table 2). The
95% CI of the allele frequency is also presented in Table 2.
Table 1: Characteristics of the NTG and HTG group
Parameter NTG (N = 105) HTG (N = 34) p value
Age 52.50 ± 11.09 51.79 ± 10.95 0.748
TC 4.85 ± 0.95 5.60 ± 1.08 0.0001
LDL 2.85 ± 0.84 3.09 ± 1.07 0.175
HDL 1.16 ± 0.19 1.11 ± 0.19 0.230
LDL/HDL 2.53 ± 0.85 2.84 ± 1.10 0.134
TG 1.22 ± 0.41 2.78 ± 0.83 <0.0001
Log TG 0.06 ± 0.17 0.43 ± 0.11 <0.0001
Values expressed in mmol/L
Table 2: Frequency distribution of various genotypes and alleles 
of APOC3 SstI polymorphism in the study population *
Genotype Observed geno-
type frequency
Expected geno-
type frequency
Allele frequency 
[95%CI]
S1S1 65 65.61 S1 = 0.687 
[0.63–0.74]
S1S2 61 59.78 S2 = 0.313 
[0.26–0.37]
S2S2 13 13.61
Total 139
* Test for Hardy-Weinberg equilibrium : Chi-square = 0.0585, df = 1, 
p = 0.8088
Table 3: APOC3 SstI polymorphism and triglyceride levels
Frequency Genotype/ Allele HTG (N = 34) NTG (N = 105) Crude OR 
(95%CI, p value)
Adjusted OR*
 (95%CI, p value)
Genotype frequency S1S1 9 (26.5%) 56 (53.3%) 1.00 (Referent) 1.00 (Referent)
S1S2 17 (50%) 44 (41.9%) 2.4 (0.98–5.90, 0.056) 2.43 (0.99–6.01, 
0.054)
S2S2 8 (23.5%) 5 (4.8%) 9.95 (2.66–37.29, 
0.0006)
9.90 (2.64–37.12, 
0.0007)
Allele frequency S1 0.515 (0.39–0.64) 0.742 (0.68–0.80)
S2 0.485 (0.36–0.61) 0.258 (0.20–0.32)
* Adjusted for age Genotypes: Chi-Square = 14.019, df = 2, p = 0.001; S1S1 vs. S1S2 + S2S2: Chi-Square = 7.445, df = 1, p = 0.006. Alleles: p = 
0.001BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/9
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To determine the association of APOC3 SstI polymor-
phism with TG levels, the study population was divided
into NTG and HTG groups. Out of 139 individuals, 34
subjects (24.46%) were in HTG group i.e. TG levels be-
yond 1.921 mmol/L. Table 3 summarize the distribution
of various genotypes and alleles of APOC3 polymorphism
between the NTG and HTG groups. The 95% CI of the al-
lele frequencies is also presented in Table 3. No significant
difference was observed between the expected and ob-
served genotype frequencies of the two groups (NTG: Chi
square = 0.9852, df = 1, p = 0.3209 and HTG: Chi square
= 0.000, df = 1 and p = 0.9960; in Hardy-Weinberg equilib-
rium). There was a significant difference in the genotypic
distribution between the NTG and HTG groups as shown
in Table 3 (Chi square = 14.019, df = 2, p = 0.001). S1S1
genotype was more frequent in the NTG group as com-
pared to the HTG group (53.3% vs. 26.5%). Conversely,
S2S2 genotype was almost five times more prevalent in
the HTG group as compared to the NTG group (23.5% vs.
4.8%). However, not much difference was observed in the
S1S2 frequency between the two groups (HTG: 50% vs.
NTG: 41.9%). In totality, 73.5% of HTG group (25/34)
were S2 carriers out of which 32% individuals (i.e. 8/25)
were S2 homozygotes. Comparatively, NTG group had
46.7%(49/105) S2 carriers, of which only 10.2%(5/49)
were S2 homozygotes. Consequently, S2 allele was almost
two times more frequent in the HTG group compared to
the NTG group (p = 0.001) as shown in Table 3.
Logistic analysis revealed a significant association of
APOC3 S2 allele with hypertriglyceridemia (Table 3). The
crude Odds ratio (OR) for S1S2 genotype (in comparison
to S1S1 genotype) was found to be 2.4 (95%CI: 0.98–
5.90), which was towards significance (p= 0.056) and did
not change much after adjusting for age (OR= 2.43, 95%
CI = 0.99–6.01, p= 0.054). The crude OR for S2S2 to de-
velop HTG (in comparison to S1S1) was found to be 9.95
(95% CI: 2.66–37.29, p = 0.0006), which was highly sig-
nificant and remained significant even after adjusting for
age (OR = 9.90, 95%CI = 2.64–37.12, p = 0.0007). In to-
tality, S2 carriers had a crude OR of 3.17 to develop HTG
(95%CI = 1.35–7.45, p = 0.008) and 3.22 (95% CI =
1.37–7.60, p= 0.007) after age adjustment.
The intergenotypic variations in lipid profile in the HTG,
NTG and total subjects are shown in Table 4. TG was sig-
nificantly different among various genotypes in the HTG
(p = 0.015, log TG: p = 0.015), the total subjects (p <
0.0001) and insignificant in the NTG group (p = 0.114,
logTG: p = 0.137). In particular, the S2S2 individuals were
associated with highest concentration of TG followed by
S1S2 and then by S1S1 in HTG group & total study popu-
lation. No significant differences were observed in TC,
LDL, HDL and LDL/HDL ratio in any of the study group
(Table 4).
Table 4: Intergenotypic variation in the lipid profile in NTG group, HTG group and total study population
Parameters Groups Genotypes (Mean ± S.D.) p value
S1S1 S1S2 S2S2
TC NTG 4.85 ± 0.98 4.82 ± 0.94 5.30 ± 0.58 0.567
HTG 5.77 ± 1.09 5.65 ± 1.22 5.31 ± 0.78 0.673
Total 4.98 ± 1.04 5.05 ± 1.08 5.31 ± 0.68 0.572
LDL NTG 2.78 ± 0.88 2.90 ± 0.81 3.31 ± 0.53 0.372
HTG 3.11 ± 1.32 3.18 ± 1.17 2.92 ± 0.47 0.865
Total 2.82 ± 0.95 2.98 ± 0.92 3.07 ± 0.51 0.526
HDL NTG 1.16 ± 0.22 1.16 ± 0.15 1.17 ± 0.06 0.99
HTG 1.06 ± 0.20 1.15 ± 0.19 1.08 ± 0.17 0.425
Total 1.14 ± 0.22 1.16 ± 0.16 1.12 ± 0.14 0.773
LDL/HDL NTG 2.50 ± 0.92 2.55 ± 0.79 2.84 ± 0.58 0.674
HTG 3.09 ± 1.70 2.77 ± 0.94 2.74 ± 0.54 0.762
Total 2.58 ± 1.06 2.61 ± 0.83 2.78 ± 0.53 0.770
TG NTG 1.28 ± 0.49 1.13 ± 0.41 1.40 ± 0.33 0.114
HTG 2.51 ± 0.44 2.60 ± 0.60 3.51 ± 1.21 0.015
Total 1.45 ± 0.58 1.54 ± 0.81 2.70 ± 1.42 <0.0001
Log TG NTG 0.08 ± 0.17 0.02 ± 0.16 0.14 ± 0.11 0.137
HTG 0.39 ± 0.07 0.40 ± 0.09 0.53 ± 0.13 0.015
Total 0.12 ± 0.19 0.13 ± 0.23 0.38 ± 0.23 0.0004
Values expressed in mmol/LBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/9
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Discussion
ApoCIII provides a strong negative charge on the surface
of lipoproteins preventing nonspecific interactions with
cell surfaces [33] and perhaps with other lipoproteins.
This may serve the function of reducing futile cycles in TG
transport by preserving the particles for high affinity inter-
actions such as with lipoprotein lipase or specific cell sur-
face receptors e.g., such as those binding to apoE or apoB.
Plasma concentrations of apoC-III in human populations
correlate well with TG levels [16,34]. In vivo apoCIII mod-
ulates the postprandial management of the TG [6] and in-
hibits the hepatic uptake of VLDL remnants [35]. The
genetically determined deficiency of apoCIII in humans
has been shown to increase the rate of TG clearance from
plasma by 6- to 7-fold [36]. A similar enhancement of TG
clearance was observed in mice made apoCIII deficient by
gene knockout experiments [6]. Overexpression of apoCI-
II produces hypertriglyceridemia in transgenic mouse
models via inhibition of clearance of TG-rich particles [4].
It is now clear that normal physiological systems respon-
sible for TG transport are partially determined by the plas-
ma content of apoCIII. Although it is not clear how this
protein contributes to the familial hypertriglyceridemic
syndromes, recent studies have found that two classes of
drugs that are effective in lowering plasma TG in these pa-
tients act through suppression of APOC3 gene transcrip-
tion in rodents [37,38].
The human APOC3 gene expression is controlled by posi-
tive and negative elements that are spread through out the
APOA1-C3-A4 gene cluster on the long arm of chromo-
some 11 [39]. Various restriction fragment length poly-
morphisms in and around the human APOC3 gene have
been associated with hypertriglyceridemia in several dis-
tinct populations [40]. The present study on SstI polymor-
phism was carried out on a random sample of 139
individuals inhabiting plains of Northern part of India.
The genotypic distribution was in good agreement with
Hardy-Weinberg equilibrium. Our study revealed a higher
frequency of rare S2 allele (0.313) than observed for most
of the Caucasians (0.00–0.11) [8–13,18,21,26] but with-
in the same range as reported for different non Caucasian
populations (0.15–0.39) [14–17,20,28–31]. Earlier Paul
et al reported the distribution of APOC3 SstI polymor-
phism in a much smaller sample of immigrant Asian Indi-
ans at U.K. (S2 = 0.19, N = 24) [41]. We attempted at
elucidating the association of APOC3 SstI polymorphism
with TG levels. Individuals having TG levels up to 1.921
mmol/L were grouped in NTG and more than 1.921
mmol/L were grouped in HTG group. S2S2 individuals
had the highest levels of TG followed by S1S2 and S1S1 in
HTG and total study population. Significantly higher fre-
quency of S2 allele in the HTG group as compared to the
NTG group suggests a strong association of the S2 allele
with higher levels of TG. Such an association of S2 allele
with higher levels of TG has been reported in studies car-
ried out on Caucasians [8–13,18,21–24], Chinese [14],
Mayans [15], Japanese [16], Koreans [17], South Africans
[19] and Arabs [20]. The biochemical basis for the associ-
ation of S2 allele with hypertriglyceridemia has yet to be
established. Dallinga-Thie et al [22,23] and Shoulders et
al [24,25] reported an association between levels of
apoCIII and S2 allele. The SstI polymorphism is located in
the 3' untranslated region of APOC3 gene. Therefore, it is
more likely that S2 allele is not etiological but in linkage
disequilibrium with other causative mutation hitherto
unknown in APOC3 or nearby gene involved in determin-
ing the TG levels. It has been suggested that certain haplo-
types generated from SstI polymorphism and promoter
polymorphism of APOC3 gene may protect or predispose
to hypertriglyceridemia [17]. In addition, SstI polymor-
phism may also influence mRNA stability [17]. Few of the
studies carried out on Caucasians [26,27], Taiwanese [28],
Japanese [29,30] and Arabs [31] did not find any signifi-
cant association between SstI polymorphism and HTG. It
has been speculated that the linkage disequilibrium be-
tween this polymorphic site and the causative mutation is
weakened or absent in some populations [24].
Ours is the first study on Asian Indians to report a strong
association of APOC3 S2 allele with hypertriglyceridemia
in Indians. The logistic analysis revealed that individuals
carrying S2 allele were 3.2 times more prone to develop
hypertriglyceridemia as compared to S1S1. Thus, S2 allele
may serve as a significant risk marker for susceptibility to
hypertriglyceridemia. This is an important finding as
Asian Indians are highly sensitive to the adverse effects of
hypertriglyceridemia [32], the risk of which is likely to in-
crease manifold with growing shift towards affluent life-
style and sedentary habits in larger fraction of our
population.
Conclusion
We found a high prevalence of rare S2 allele of APOC3
gene in HTG individuals. Further, this allele was more fre-
quent in our study population as compared to Cauca-
sians. Since HTG is considered as a risk factor for CAD in
Asian Indians, there is an urgent need to evaluate the as-
sociation of APOC3 SstI polymorphism with the risk of
developing coronary artery disease in Asian Indians.
Materials and Methods
One hundred and thirty nine healthy male volunteers
from plains of northern part of India (mean age: 52.32 ±
11.02 years) were enrolled in the study. The subjects were
scrutinized on the basis of standard questionnaire. They
shared fairly common socio-cultural background and
comparable dietary habits. All underwent routine bio-
chemical tests (hemoglobin, urea & sugar) and blood
pressure measurement. Subjects having angina or any his-BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/9
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tory of myocardial infarction were excluded from the
study. The research was undertaken with the approval of
ethical committee set by All India Institute of Medical Sci-
ences, New Delhi and its guidelines were observed.
Venous blood was collected from each individual after at
least 12 hours of fasting. Lipid profile was monitored us-
ing enzymatic kits (Randox laboratories limited, UK).
The study subjects were classified into normotriglyceri-
demic group (NTG: N = 105, TG < = 1.921 mmol/L) and
hypertriglyceridemic group (HTG: N = 34, TG>1.921
mmol/L) based on the normal range of the TG calibrated
at AIIMS, which is 0.791–1.921 mmol/L. The calibration
was done on data obtained from huge number of serum
samples. All the chemicals used in the study were pro-
cured from Sigma Chemical Co., USA, if not specified.
DNA was extracted from blood by salting out method
[42]. 100–500 ng of DNA was amplified in a thermocycler
(PTC-100, MJ Research Inc., USA) using 1 unit of Taq
DNA Polymerase (Life Technologies Inc., USA) in a 25 ul
reaction mixture containing 10 picomole forward primer:
5'-CAT GGT TGC CTA CAG GAG TTC-3'and reverse prim-
er: 3'-TGA CCT TCC GCA CAA AGC TGT-5' (MWG Bio-
tech GmbH, Germany)[8]. The PCR mixture also
contained 10% DMSO and 5 mM dNTPs (Life Technolo-
gies Inc., USA). DNA was initially denatured for 5 minutes
at 95°C, annealed at 58°C for 3 minutes and at 72°C for 5
minutes. The cycling conditions were set to heat the sam-
ples at 95°C for 50 seconds, at 58°C for 45 seconds and at
72°C for 1 minute. The cycle was repeated 40 times fol-
lowed by final extension at 72°C for 10 minutes.
Nine microlitre of the PCR product was digested at 37°C
overnight with 10 units of SacI restriction enzyme (New
England Biolabs Inc., USA) in the presence of 1 ul of 10X
buffer provided with the restriction enzyme. The digested
PCR product was resolved on a 3% agarose gel using
1XTBE buffer (89 mM Tris Borate, 2 mM EDTA, pH8.3) at
80 V for at least 1 hour and visualized by ethidium bro-
mide staining on a U. V. transilluminator. The presence of
the SstI site yields two fragments of 225 bp and 371 bp,
while in the absence of the site one fragment of 596 bp is
observed. The wild type allele lacking the restriction site is
called as S1 and the allele containing the SstI restriction
site is designated as S2 allele.
Allelic frequencies were estimated by gene-counting
method. The sample-size dependent standard error of al-
leles was calculated in terms of 95% confidence interval
(CI) of the estimates. Chi-square goodness-of-fit was used
to verify the agreement of the observed genotype frequen-
cies with those expected ones (Hardy-Weinberg equilibri-
um) in various study groups. Chi-square test was applied
to compare genotypic frequencies between the two
groups. Contingency table approach (Fisher's RxC test)
was used to determine if there is significant differences in
allele frequencies among the group of individuals. The bi-
ochemical characteristics of the individuals in various
genotypic groups were expressed in terms of mean ±
standard deviation (S.D.) and were compared using anal-
ysis of variance (Annova). Triglycerides values were also
log transformed because the test of homogeneity of vari-
ance was found to be significant. Logistic analysis with en-
ter method was performed. S1S1 genotype was taken as
the reference and the odds ratio with 95% confidence in-
terval was calculated for S1S2 and S2S2 genotypes indi-
vidually and taken together. Hypertriglyceridemia was
entered as dependent variable with NTG = 0 and HTG = 1.
All the statistical analysis was preformed using SPSS (Sta-
tistical Package for Social Sciences) for windows (version
7.5.10, SPSS Inc., Chicago). Statistical significance was set
at p < 0.05.
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